Electrophysiology & Arrhythmia

A high intake of grapefruit juice—and other dietary flavonoids found in fruits, vegetables, tea and wine—could correspond to QT interval prolongation in healthy individuals and those with heart disease, leaving them vulnerable to serious arrhythmias like torsades-de-pointes.

A trio of studies presented at the Heart Rhythm Society’s 40th annual scientific sessions earlier this month highlight significant disparities in patient access to implantable cardiac devices—particularly in women and black patients.

AliveCor has been granted FDA clearance for KardiaMobile 6L, the world’s first publicly available six-lead personal electrocardiogram device.

The FDA is updating azithromycin drug labels to reflect evidence that the medication can contribute to a rare heart rhythm abnormality known as torsades de pointes.

The Heart Rhythm Society issued a first-ever consensus statement on the evaluation, risk stratification and management of arrhythmogenic cardiomyopathy at its annual conference in San Francisco this spring.

South Korean researchers are working on packing the ability to monitor heart health and detect signs of atrial fibrillation into what might be the smallest cardiology wearable to date: a “smart ring.”

BioCardia’s AVANCE steerable introducer family has received FDA 510(k) clearance, the company announced May 8.

Research presented at the Heart Rhythm Society’s 40th annual scientific sessions in San Francisco May 7 suggests heart patients with implanted electronic devices know less about their therapies than they think they do.

The FDA issued an alert May 7 warning patients with certain implanted Medtronic pacemakers or cardiac resynchronization therapy pacemakers (CRT-Ps) and their care teams to check for premature battery depletion in their devices after defects resulted in three reports and one patient death.

Individuals with heart failure with preserved ejection fraction (HFpEF) and atrioventricular block might benefit more from cardiac resynchronization therapy (CRT) than conventional right ventricular (RV) pacing, according to research published in JACC: Heart Failure.

Omron Healthcare launched its latest innovation, Complete, May 1, marking the first time a blood pressure (BP) monitor with electrocardiogram (ECG) capabilities has hit the commercial market.

The FDA on May 1 announced it cleared Medtronic’s Attain Stability Quad MRI SureScan left heart lead for commercial use in the U.S.